Jubilant Ingrevia Ltd

Jubilant Ingrev. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Ingrevia Ltd

₹ 626 1.23%
09 Jun - close price
jubilantingrevia.com BSE: 543271 NSE: JUBLINGREA
About

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

Key Points

Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider.

Website BSE NSE
  • Market Cap ₹ 9,965 Cr.
  • Current Price ₹ 626
  • High / Low ₹ 852 / 535
  • Stock P/E 34.6
  • Book Value ₹ 196
  • Dividend Yield 0.80 %
  • ROCE 11.4 %
  • ROE 9.51 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 29.6%
  • Company's working capital requirements have reduced from 29.4 days to 22.0 days

Cons

  • Stock is trading at 3.19 times its book value
  • Company has a low return on equity of 8.48% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -6.25%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE 500 Nifty 500 Nifty500 Shariah BSE Commodities BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,145 1,075 1,020 966 1,074 1,024 1,045 1,057 1,051 1,038 1,121 1,051 1,179
1,043 958 902 871 983 915 921 918 905 896 985 924 1,016
Operating Profit 102 117 118 96 91 110 124 138 147 142 135 126 163
OPM % 9% 11% 12% 10% 8% 11% 12% 13% 14% 14% 12% 12% 14%
9 8 9 9 10 10 10 9 8 11 11 -4 9
Interest 6 11 13 15 14 14 15 12 14 13 12 12 12
Depreciation 30 32 34 34 36 39 40 40 39 41 41 45 48
Profit before tax 76 81 80 55 51 66 80 96 102 100 93 65 112
Tax % 31% 29% 28% 30% 43% 26% 26% 27% 27% 25% 25% 28% 23%
52 58 57 39 29 49 59 69 74 75 69 47 86
EPS in Rs 3.28 3.62 3.61 2.42 1.84 3.06 3.70 4.36 4.65 4.71 4.36 2.94 5.43
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 684 4,949 4,773 4,136 4,178 4,388
0 567 4,108 4,224 3,708 3,658 3,821
Operating Profit -0 117 841 549 427 519 567
OPM % 17% 17% 11% 10% 12% 13%
0 -10 22 32 29 38 27
Interest 0 7 31 22 53 56 49
Depreciation 0 22 123 122 136 158 175
Profit before tax -0 77 709 437 268 344 370
Tax % 0% 30% 33% 30% 32% 27% 25%
-0 54 477 308 183 251 278
EPS in Rs -3.40 3.41 29.93 19.31 11.48 15.77 17.45
Dividend Payout % 0% 10% 17% 26% 43% 31% 14%
Compounded Sales Growth
10 Years: %
5 Years: 45%
3 Years: -3%
TTM: 5%
Compounded Profit Growth
10 Years: %
5 Years: 35%
3 Years: -2%
TTM: 14%
Stock Price CAGR
10 Years: %
5 Years: 2%
3 Years: 13%
1 Year: -10%
Return on Equity
10 Years: %
5 Years: 11%
3 Years: 8%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.05 16 16 16 16 16 16
Reserves -0 1,907 2,417 2,650 2,722 2,911 3,110
0 556 238 407 740 764 792
0 888 1,111 1,176 1,241 1,324 1,566
Total Liabilities 0 3,366 3,782 4,249 4,719 5,015 5,484
0 1,805 1,798 1,846 2,539 2,581 3,183
CWIP 0 65 174 525 331 525 154
Investments 0 50 6 8 15 37 33
0 1,446 1,804 1,870 1,834 1,872 2,113
Total Assets 0 3,366 3,782 4,249 4,719 5,015 5,484

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 112 453 462 430 508 524
0 33 -71 -469 -568 -389 -276
0 -72 -418 42 144 -129 -155
Net Cash Flow 0 73 -36 35 6 -9 93
Free Cash Flow 0 85 225 -16 -136 156 235
CFO/OP 0% 106% 69% 98% 111% 113% 111%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 251 43 39 50 53 65
Inventory Days 601 119 146 160 163 140
Days Payable 685 104 113 131 141 150
Cash Conversion Cycle 167 58 72 80 75 55
Working Capital Days 220 49 42 37 29 22
ROCE % 8% 29% 16% 10% 11% 11%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025
Customer Base Size
Count

Log in to view insights

Please log in to see hidden values.

Login
Number of Manufacturing Plants
Count
Number of Products in Portfolio
Count
Number of Pyridine Derivatives with Global #1 Position
Count
Renewable Power Share in Total Consumption
%
Workforce Strength
Employees
New Molecules Won in last 12 months
Count
Active CDMO Opportunity Funnel
Count
R&D Pipeline (Products under development)
Count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

7 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 45.22% 45.22% 45.22% 45.22%
6.15% 6.30% 6.35% 6.58% 6.55% 7.22% 6.89% 7.12% 6.96% 5.96% 6.15% 6.49%
6.72% 9.18% 11.17% 13.60% 14.07% 15.47% 15.99% 15.91% 21.81% 23.04% 24.00% 24.76%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.02%
34.83% 32.22% 30.17% 27.53% 27.10% 25.09% 24.90% 24.76% 25.30% 24.94% 23.80% 22.53%
0.82% 0.82% 0.82% 0.81% 0.81% 0.77% 0.74% 0.73% 0.72% 0.82% 0.80% 0.98%
No. of Shareholders 1,86,2941,73,5331,62,2021,50,3881,42,7361,25,3671,24,8301,20,4061,23,7481,25,7491,17,5291,12,696

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls